



Minerva Access is the Institutional Repository of The University of Melbourne

**Author/s:**

Nguyen, BN;Hew, SA;Ly, J;Shin, HY;Wong, JC;Yeung, E;McKendrick, AM

**Title:**

Acute caffeine ingestion affects surround suppression of perceived contrast

**Date:**

2018-01-01

**Citation:**

Nguyen, B. N., Hew, S. A., Ly, J., Shin, H. Y., Wong, J. C., Yeung, E. & McKendrick, A. M. (2018). Acute caffeine ingestion affects surround suppression of perceived contrast. *Journal of Psychopharmacology*, 32 (1), pp.81-88. <https://doi.org/10.1177/0269881117725684>.

**Persistent Link:**

<https://hdl.handle.net/11343/191904>

1 **1. Article type:** Original paper

2 **2. Corresponding author:** Bao Nguyen, University of Melbourne

3 C/O Department of Optometry and Vision Sciences, Level 4 Alice Hoy (Building 162)

4 Monash Road, University of Melbourne, Victoria, 3010 Australia

5 Email: [bnguyen@unimelb.edu.au](mailto:bnguyen@unimelb.edu.au)

6 **3. Title (max 50 words):** Acute caffeine ingestion affects surround suppression of  
7 perceived contrast

8 **Running head (max 50 characters):** Caffeine affects perceptual surround suppression

9 **4. Authors:** Bao N Nguyen<sup>1</sup>, Sui-Ann Hew<sup>1</sup>, John Ly<sup>1</sup>, Hee-Young Shin<sup>1</sup>, Jessica Wong<sup>1</sup>,  
10 Emily Yeung<sup>1</sup>, Allison M McKendrick<sup>1</sup>

11 <sup>1</sup>Department of Optometry and Vision Sciences, University of Melbourne, Parkville,  
12 Victoria, Australia

13 **5. Abstract:** (247 words)

14 Caffeine is a widely used psychostimulant that is associated with increased  
15 acetylcholine levels in mammalian brain and acetylcholinesterase antagonism.  
16 Acetylcholine, a neuromodulator, plays an important role in the processing of visual  
17 information. One key example in human vision thought to at least partly involve  
18 cholinergic neuromodulation is perceptual surround suppression of contrast, whereby  
19 the perceived contrast of a pattern is altered by the presence of a neighbouring

20 pattern. Perceptual surround suppression is weaker with pharmacological  
21 administration of donepezil (a centrally-acting acetylcholine enzyme inhibitor) in  
22 healthy human observers. Here, we test whether temporarily manipulating caffeine  
23 levels (from complete washout to a controlled dose of caffeine) has a similar effect on  
24 perceptual surround suppression in 21 healthy young adults (aged 20-24, 11 females).  
25 Neither ingestion of a caffeine pill nor placebo altered contrast judgments when the  
26 target pattern was presented on a uniform grey background ( $p=0.54$ ). With caffeine  
27 ingestion, perceptual surround suppression strength was reduced relative to baseline  
28 (prior to pill ingestion,  $p=0.003$ ) and placebo ( $p=0.029$ ), irrespective of whether the  
29 surround was oriented parallel or orthogonal to the central target. While daily habitual  
30 caffeine consumption of low-to-moderate doses (<400 mg/day, estimated from a  
31 written questionnaire) is not predictive of performance, our study indicates that acute  
32 consumption of caffeine on the day of testing influences perceptual surround  
33 suppression strength. Perceptual surround suppression is predominantly attributed to  
34 inhibitory processes involving the major cortical inhibitory neurotransmitter, GABA.  
35 Our results point to the involvement of other neuromodulators, possibly cholinergic, in  
36 perceptual surround suppression.

37 **Clinical trials registration:** This trial is registered in the Australian New Zealand Clinical  
38 Trials Registry ([www.ANZCTR.org.au/ACTRN12616000423415p.aspx](http://www.ANZCTR.org.au/ACTRN12616000423415p.aspx), Trial ID:  
39 #12616000423415).

40 **Keywords:** caffeine, acetylcholine, surround suppression, vision, visual perception

41

42 **Number of figures:** 4

43 **Number of tables:** 0

44 **Number of words:** 4397 words (main text)

45

46 **Introduction**

47 Caffeine is the most widely consumed psychoactive substance. In addition to its well-  
48 known stimulant effects via adenosine receptor blockade in the brain (Fredholm et al.,  
49 1999; Ribeiro and Sebastiao, 2010), caffeine can influence neurotransmission,  
50 including effects on the cholinergic (Pohanka, 2014), dopaminergic (Garrett and  
51 Griffiths, 1997), noradrenergic (Berkowitz et al., 1970), and serotonergic (Berkowitz  
52 and Spector, 1971) pathways. Acetylcholine is a neuromodulator that is implicated in  
53 visual sensory processing. A well-studied visual perceptual phenomenon that is  
54 thought to at least partially involve acetylcholine (Kosovicheva et al., 2012) is surround  
55 suppression of contrast. Surround suppression of contrast describes the phenomena  
56 where the apparent contrast of a visual stimulus can be markedly affected by its  
57 surrounding context. Typically, the apparent contrast of a target (e.g. a striped grating  
58 pattern) is reduced when surrounded by a pattern of higher contrast, compared to  
59 when viewed in isolation (Cannon and Fullenkamp, 1991; Chubb et al., 1989; Ejima and  
60 Takahashi, 1985). The strength of such perceptual suppression depends on a range of  
61 stimulus characteristics, such as the contrast (Ejima and Takahashi, 1985; Xing and  
62 Heeger, 2001) and orientation (Cavanaugh et al., 2002; Levitt and Lund, 1997; Xing and  
63 Heeger, 2000) of the neighbouring stimulus (the surround) relative to the central  
64 target. Perceptual surround suppressive effects show strong quantitative agreement

65 with responses measured from human primary visual cortex (V1) using fMRI (Zenger-  
66 Landolt and Heeger, 2003; Haynes et al., 2003; Williams et al., 2003; Pilhaja et al.,  
67 2008; Joo et al., 2012), which suggests V1 as the earliest cortical area with the  
68 neuronal architecture capable of mediating perceptual surround suppressive effects in  
69 humans. Convergent evidence from primate work also points to a complex interaction  
70 between intra-V1, feedforward and feedback connections to V1 as contributing to  
71 visual surround suppression (Angelucci and Bressloff, 2006).

72

73 A recent study demonstrated that ingestion of the centrally-acting acetylcholine  
74 enzyme inhibitor, donepezil (Kosasa et al., 1999; Rogers et al., 1991), reduces  
75 perceptual surround suppression of contrast in healthy adults (Kosovicheva et al.,  
76 2012). An alternate method for manipulating acetylcholine levels may be caffeine  
77 ingestion. Caffeine administration enhances acetylcholine release in the hippocampus  
78 of awake, freely moving rats (Carter et al., 1995) and in stimulated cerebral cortex  
79 slices of rats naïve to caffeine (Corradetti et al., 1986). In addition, caffeine shows  
80 antagonistic effects on human acetylcholinesterase samples (Pohanka and Dobes,  
81 2013). There is also convergent evidence from human behavioural work supporting a  
82 role for caffeine in influencing the cholinergic system. Scopolamine is an anti-  
83 cholinergic drug that adversely affects performance on cognition tests. Riedel et al

84 (1995) demonstrated that scopolamine-induced deficits in short-term memory could  
85 be attenuated by acute consumption of caffeine, suggesting that caffeine has  
86 cognition-enhancing properties by acting, at least partly, through cholinergic  
87 pathways. If caffeine has cholinergic effects and potentially increases acetylcholine  
88 levels in the human brain, its ingestion may influence the strength of perceptual  
89 surround suppression of contrast.

90

91 In this study, we test the hypothesis that acute caffeine ingestion in healthy observers  
92 affects perceptual surround suppression of contrast by using a common task that is  
93 often used to investigate spatial contextual interactions in human vision (Zenger-  
94 Landolt and Heeger, 2003; Yoon et al., 2009; Yoon et al., 2010; Kosovicheva et al.,  
95 2012). We predicted that perceptual surround suppression strength would decrease  
96 following caffeine consumption (similar to the effects of donepezil). We presented  
97 surround grating patterns that were oriented parallel and orthogonal to the target  
98 pattern to determine whether the effect of caffeine on perceptual suppression was  
99 orientation-dependent, as there are both orientation specific and non-specific aspects  
100 of perceptual surround suppression (Schallmo and Murray, 2016). If caffeine acts via a  
101 similar mechanism as donepezil to influence contrast perception, we hypothesise that  
102 the reduction in perceptual surround suppression following caffeine would only be

103 present for the parallel surround condition, as previously reported by Kosovicheva et al  
104 (2012).

105

## 106 **Methods**

### 107 ***Participants***

108 Experimental procedures were approved by the Human Research Ethics Committee of  
109 the University of Melbourne (ID #1646382) and complied with the tenets of the  
110 Declaration of Helsinki. Written informed consent was obtained prior to testing. Our  
111 research hypothesis was based on a previous study (Kosovicheva et al., 2012) that  
112 measured the effect of donepezil on surround suppression of perceived contrast in a  
113 group of 19 healthy, young observers (mean age 26 years), compared to a placebo pill.  
114 In that study, a paired t-test (drug vs placebo) found a significant difference in  
115 performance (group mean difference=1% contrast, standard deviation=1.3% contrast)  
116 with 90% power (alpha=0.05, 2-tailed), rejecting the null hypothesis that the mean  
117 difference was 0% contrast. We aimed for a similar number of participants in our  
118 sample to be able to detect a comparable difference in perceptual surround  
119 suppression with and without acute caffeine ingestion. The final sample size was 21  
120 young adults (aged 20-24, 11 females). All participants were screened to ensure visual  
121 acuity of 6/7.5 or better in each eye with habitual refractive correction, and no

122 systemic conditions (e.g. diabetes, epilepsy) or medications (e.g. antidepressants)  
123 known to affect visual function.

124

### 125 ***Caffeine questionnaire***

126 Participants completed a questionnaire modified from Modi et al. (2010) to evaluate  
127 caffeine intake over the past month. Participants indicated the frequency of  
128 consumption of food, beverages, and medications containing caffeine. Estimates of  
129 daily caffeine intake (mg/kg/day) were calculated based on the caffeine content (mg)  
130 per standard unit of consumption (see Table 1 from Modi et al., 2010) and normalised  
131 to the participant's weight (kg).

132

### 133 ***Experimental design***

134 The experiment was a double-blind, placebo-controlled, randomised cross-over design.  
135 Participants attended two test sessions of up to 90 minutes each. As per previous  
136 studies (Haskell et al., 2005; Colzato et al., 2005), participants refrained from  
137 consuming caffeine for 24 hours prior to a test visit. A 12-hour caffeine washout period  
138 is sufficient to reduce salivary caffeine levels to negligible levels (< 1mg/mL) in habitual  
139 and non-habitual caffeine consumers (Haskell et al., 2005).

140

141 The first visit included the vision screening and caffeine questionnaire. At each visit,  
142 participants completed pre-drug baseline visual perceptual tests (described in the next  
143 section) and then consumed one of two types of pills with water:

144

145 (1) Caffeine (200 mg): 2 x 'No Doz Plus' tablets (Key Pharmaceuticals, Macquarie  
146 Park, Australia). Each tablet consists of 100 mg caffeine, 10 mg Vitamin B1, and  
147 10 mg Vitamin B3.

148 (2) Placebo (200 mg): 2 x 'Betamin' tablets (Sanofi-Aventis, Macquarie Park,  
149 Australia). Each tablet consists of 100 mg Vitamin B1.

150

151 The pills were white, uncoated, round tablets of approximately the same size with no  
152 engravings. The caffeine dosage (200 mg) was exactly 2 tablets and was chosen  
153 because a comparable amount of oral caffeine (250 mg) elicits changes in the blood-  
154 oxygen dependent magnetic resonance imaging (MRI) signal from the visual cortex in  
155 healthy adults (Laurienti et al., 2002). Doses of 250 mg caffeine have also yielded  
156 measurable changes on a visual feature binding task in healthy young adults (Colzato  
157 et al., 2005). The magnitude and timing of peak plasma caffeine levels following oral  
158 caffeine ingestion varies considerably amongst individuals (Fredholm et al., 1999;  
159 Robertson et al., 1978). Nevertheless, we constrained the visual perceptual testing to

160 occur within a specified time frame based on previous measures of the approximate  
161 time when an absolute dose of 250 mg caffeine reaches its peak plasma concentration  
162 in the majority (89%) of healthy young individuals (Robertson et al., 1978). Hence,  
163 participants waited between 30-60 minutes, during which time participants waited  
164 quietly in the testing room, before repeating the visual perceptual tests. No other tasks  
165 were completed during the test session. The order of pill administration was  
166 randomised and prepared by author BNN who was neither tested nor conducted  
167 participant testing, so that all other investigators and participants were blinded. The  
168 second session was scheduled at least 2 days after the first to ensure caffeine washout.

169

### 170 ***Visual tasks***

171 Participants were refractively corrected for near binocular viewing (40 cm). Gamma-  
172 corrected stimuli were generated off-line in Matlab R2013b (Mathworks, Natick, MA,  
173 USA) and presented on an iPad-3 tablet device (Apple Inc., Cupertino, CA, United  
174 States; frame rate: 60 Hz; screen resolution: 2048 × 1536 pixels) using the open-access  
175 platform 'PsyPad' (Turpin et al., 2014). The PsyPad app selects which stimulus image to  
176 display from the pre-generated library of images according to a customisable staircase  
177 procedure. The image library and staircase configuration used for this study can be  
178 downloaded from the PsyPad server (<http://server.psypad.net.au>). An example test

179 ('Annular centre-surround task: which quadrant is the odd one out?') can be viewed in  
180 Psypad Demo mode.

181

182 Stimuli were drawn as per Kosovicheva et al (2012), except that the stimulus size was  
183 scaled (reduced to 0.8 of the original size used by Kosovicheva et al 2012) to fit the  
184 iPad screen at the working distance (40 cm). A central black fixation point was  
185 provided. The image background was set to mean luminance ( $172 \text{ cd/m}^2$  for an iPad at  
186 constant maximum brightness). Three surround conditions were tested: (1) No  
187 surround (2) Parallel surround (3) Orthogonal surround. For the 'no surround'  
188 condition, an annulus (inner radius:  $2.5^\circ$ , outer radius:  $5^\circ$ ) was presented in the centre  
189 of the screen, consisting of a vertical sinusoidal grating (1.1 cycles/degree, 20%  
190 contrast) divided into four quadrants (Figure 1A). One quadrant was randomly chosen  
191 to be of variable contrast. The stimulus appeared for 200 ms to minimise saccadic eye  
192 movements. Participants chose the odd quadrant out (four-alternative forced choice,  
193 4AFC). For the remaining conditions (Figures 1B and 1C) the task was the same, except  
194 that the annulus was surrounded by sinusoidal gratings of the same spatial frequency  
195 and phase extending from  $0\text{-}2.5^\circ$  radius and from  $5\text{-}10^\circ$  radius (80% contrast).

196

197 Increment detection thresholds (relative to 20% reference contrast) were measured  
198 for each quadrant using four interleaved 2-down 1-up staircases of four reversals (step  
199 sizes: 4%, 2%, 1%, 1%), and were repeated twice. The staircases began at a supra-  
200 threshold increment level (20% contrast increment for no surround, 40% contrast  
201 increment for surround conditions). Thresholds were estimated at approximately the  
202 70% probability of seeing (Wetherill and Levitt, 1965). The final threshold was the  
203 average of the final two reversals of the two repeats, averaged across all four  
204 quadrants.

205


206 The no surround condition was always tested first for training purposes, and because  
207 performance on this baseline task does not vary considerably among individuals. The  
208 remaining tasks were randomised, with half the group performing the parallel  
209 surround condition first (and vice versa) to balance for learning and/or fatigue effects.  
210 The visual perceptual tests took approximately 15 minutes, in addition to practice runs  
211 and rest breaks between trials.

212

### 213 ***Statistical analysis***

214 SPSS V22.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data were  
215 tested for normality (Kolmogorov-Smirnov test) and compared using a repeated

216 measures analysis of variance (RM-ANOVA). Huynh-Feldt adjustments were made for  
217 non-spherical data. To compare the strength of suppression, a 'suppression index' was  
218 calculated (surround threshold/no surround threshold). A ratio of 1 indicates no effect  
219 of the surround. An index >1 indicates suppression, i.e. compared to having no  
220 surround, a larger contrast increment was required to reliably detect the odd  
221 quadrant. Cohen's *d* effect sizes were calculated to measure the change in suppression  
222 from baseline after caffeine ingestion, where effect sizes of  $d = 0.2, 0.5, 0.8$  were  
223 considered small, medium, and large effects, respectively (Cohen, 2013). For all  
224 comparisons,  $p < 0.05$  was considered statistically significant.



225

226 **Figure 1.** Example stimuli used to measure perceptual surround suppression. Contrast  
 227 increment detection thresholds were measured for three surround conditions: (A) No  
 228 surround (B) Parallel surround (C) Orthogonal surround. Participants chose which of  
 229 the four quadrants was the odd one out (the 'target') relative to the rest of the  
 230 annulus (20% reference contrast). The surround was 80% contrast. In these examples,  
 231 the top-right hand quadrant of the central annulus is the odd one out.

232 **Results**

233 All participants completed the testing and were asked to guess which pill had been  
234 consumed at each of the two visits. The proportion of correct responses (62%, 13 of 21  
235 participants) was not significantly different from chance (50% guess rate; chi-square  
236 test of proportions:  $p=0.44$ ), indicating a successful blinding procedure. The median  
237 wait time between pill ingestion and repeat visual perceptual testing was 35 minutes  
238 for caffeine (range: 30-56 minutes) and 33 minutes for placebo (range: 30-52 minutes).  
239 The distribution of time post-pill ingestion was the same for the two interventions  
240 (Kolmogorov-Smirnov test:  $p=0.59$ ).

241

242 ***Baseline contrast increment thresholds***


243 We first considered whether baseline performance prior to pill ingestion varied  
244 systematically across the two visits. Overall, thresholds were not significantly different  
245 at the two visits (RM-ANOVA main effect of visit:  $F(1,20)=0.55$ ,  $p=0.47$ ,  $\eta_p^2=0.03$ ), but  
246 were different for the three surround conditions (main effect of surround:  
247  $F(2,40)=63.11$ ,  $p<0.0001$ ,  $\eta_p^2=0.76$ ). There was no interaction between visit and  
248 surround condition ( $F(2,40)=0.35$ ,  $p=0.71$ ,  $\eta_p^2=0.02$ ), indicating that performance on all  
249 tasks was similar across test sessions. Hence, baseline data were pooled across both  
250 visits for subsequent comparisons. Consistent with previous literature in healthy

251 observers (Kosovicheva et al., 2012; Yu and Levi, 2000; Xing and Heeger, 2000; Cannon  
252 and Fullenkamp, 1991), contrast increment thresholds were higher for the parallel  
253 (mean  $\pm$  standard deviation: 13.31%  $\pm$  4.32%) than orthogonal condition (10.38%  $\pm$   
254 3.06%), relative to the no surround condition (4.74%  $\pm$  1.10%), demonstrating the  
255 expected pattern of orientation-dependent surround suppression prior to any  
256 intervention.

257

#### 258 ***Effect of interventions on the no surround condition***

259 Our measure of surround suppression strength (suppression index) depends on  
260 performance on the no surround condition. We therefore determined whether the  
261 pills (caffeine versus placebo) had an effect on the no surround condition. No effect of  
262 intervention was found when baseline contrast increment thresholds (average of 2  
263 visits) were compared with the thresholds observed following ingestion of caffeine and  
264 placebo (Figure 2, main effect of intervention:  $F(2,40)=0.63$ ,  $p=0.54$ ,  $\eta_p^2=0.03$ ).



265

266 **Figure 2.** Mean contrast increment detection thresholds for the no surround condition  
267 following different interventions (baseline, caffeine, placebo). Error bars are the 95%  
268 confidence intervals of the mean.


269

270 ***Effect of intervention on surround suppression strength***

271 We found a main effect of intervention on surround suppression strength (Figure 3;  
272 Huynh-Feldt  $\epsilon=0.80$ ,  $F(1.59,31.82)=8.79$ ,  $p=0.002$ ,  $\eta_p^2=0.31$ ). After taking the caffeine  
273 pills, suppression strength was reduced for both parallel (Cohen's  $d=0.53$ ) and  
274 orthogonal ( $d=0.54$ ) surround conditions relative to baseline (Bonferroni pairwise  
275 comparisons:  $p=0.003$ ) and placebo ( $p=0.029$ ). There was no difference in suppression  
276 index between placebo and baseline ( $p>0.05$ ), indicating that only caffeine, and not  
277 the vitamin pill, altered visual performance.

278


279 Figure 4 plots the 'effect of caffeine' as the difference in suppression between having  
280 no caffeine (average of placebo and baseline) and having caffeine. The reduction in  
281 surround suppression strength following caffeine ingestion was similar for parallel and  
282 orthogonal surrounds (intervention x surround interaction: Huynh-Feldt  $\epsilon=0.69$ ,  
283  $F(1.39,27.70)=0.38$ ,  $p=0.61$ ,  $\eta_p^2=0.02$ ).



284

285 **Figure 3.** Effect of intervention (baseline, placebo or caffeine) on suppression index. A  
 286 suppression index of 1 indicates no effect of the surround; an index >1 indicates  
 287 surround suppression. Error bars are the 95% confidence intervals of the mean.

288



289

290 **Figure 4.** Mean effect of caffeine (difference between having no caffeine versus having  
291 caffeine) on suppression index. The average difference was above 0 (horizontal dotted  
292 line) regardless of surround condition, indicating that caffeine ingestion reduced  
293 suppression relative to baseline and placebo. Error bars are the 95% confidence  
294 intervals of the mean.

295

296 ***Relationship to habitual caffeine consumption***

297 Estimates of daily caffeine intake normalised to an individual's weight (mg/kg/day)  
298 ranged from 0.15 to 6.26 mg/kg/day (median = 1.57 mg/kg/day). The highest habitual  
299 caffeine consumption observed in our cohort was 356 mg/day, which is slightly more  
300 than 2.5 cups of coffee per day. Hence, the range of habitual caffeine consumption in  
301 this study was low to moderate only. There was no relationship between the effect of  
302 caffeine on suppression index and daily caffeine intake estimates (Pearson correlation  
303 analysis: parallel  $r=-0.18$ ,  $p=0.44$ ; orthogonal  $r=-0.10$ ,  $p=0.65$ ). This implies that after  
304 caffeine washout (in this case, 24 hours), acute caffeine consumption affects  
305 perceptual surround suppression independent of a person's reported routine caffeine  
306 consumption.

307

308 **Discussion**

309 We found that visual perceptual surround suppression was altered relative to baseline  
310 after a controlled dose of caffeine. Visual surround suppression tasks are considered  
311 perceptual analogues of neuronal centre-surround suppression in visual cortex,  
312 because stimulus properties (e.g. orientation, contrast) similarly influence human  
313 perception and primate visual cortical neural responses (Cannon and Fullenkamp,  
314 1991; Chubb et al., 1989; Shushruth et al., 2013; Xing and Heeger, 2000; Yu et al.,

315 2001). Numerous studies have measured perceptual surround suppression to  
316 investigate proposed alterations in neuronal mechanisms underlying the healthy  
317 ageing process (Karas and McKendrick, 2009; Karas and McKendrick, 2012), migraine  
318 (Battista et al., 2011), Alzheimer's disease (Zhuang et al., 2016), schizophrenia (Dakin  
319 et al., 2005; Yoon et al., 2009), depression (Golomb et al., 2009), and bipolar disorder  
320 (Schallmo et al., 2015). Perceptual surround suppression has even been considered a  
321 potential translational tool for use in clinical trials for schizophrenia (Barch et al., 2012;  
322 Gold et al., 2012). Although the average effect of caffeine relative to baseline  
323 performance is small (mean 0.07 difference in suppression index, see Figure 4),  
324 average group differences between control and clinical populations in perceptual  
325 surround suppression strength vary approximately from 0.14-0.15 in migraine (Battista  
326 et al., 2011), Alzheimer's (Zhuang et al., 2017), depression (Golomb et al., 2009) and  
327 bipolar disorder (Schallmo et al., 2015) to 0.35-0.4 in schizophrenia (Yoon et al., 2009)  
328 and healthy ageing (Karas and McKendrick 2012). Our small but statistically significant  
329 effect of caffeine constitutes between 17-48% of previously reported average group  
330 differences in perceptual surround suppression. Our findings therefore have far-  
331 reaching implications for the interpretation of research findings. Peak concentration of  
332 oral caffeine occurs within 30-60 minutes (Fredholm et al., 1999; Robertson et al.,  
333 1978), half of which remains in the body 4-5 hours after initial ingestion (Blanchard

334 and Sawers, 1983; Cook et al., 1976). Thus, any caffeine consumed by a participant  
335 could still be present at significant plasma concentrations hours later on the same day.  
336 We demonstrate that oral caffeine ingestion can affect perceptual tests of surround  
337 suppression in as little as 30 minutes, suggesting that caffeine levels may need to be  
338 controlled for future experimental work.

339

340 Facilitatory effects on mood, vigilance, and performance on psychomotor and  
341 cognitive tasks following acute caffeine ingestion are well-documented (Smit and  
342 Rogers, 2000; Haskell et al., 2005; Attwood et al., 2007; Adan and Serra-Grabulosa,  
343 2010), and are attributed to caffeine's antagonistic action at the level of adenosine  
344 receptors in the central nervous system (Fredholm et al., 1999; Ribeiro and Sebastiao,  
345 2010). Caffeine also influences the formation and release of a variety of  
346 neurotransmitters that are implicated in cognition, including noradrenaline, serotonin,  
347 acetylcholine, and dopamine (reviewed by Nehlig et al., 1992). In our case, improved  
348 vigilance or attention does not readily explain the reduction in perceptual surround  
349 suppression of contrast because increment contrast detection thresholds for the no  
350 surround condition were unaffected by caffeine ingestion (see Figure 2). Nevertheless,  
351 given caffeine's ability to modulate activation of cortical areas related to attention  
352 (Serra-Grabulosa et al., 2010), it is worth considering whether attention may be a

353 contributing factor in our study. A specific form of visual spatial attention, ‘feature-  
354 based’ attention, has recently been shown to modulate human perceptual surround  
355 suppression (Flevaris and Murray, 2015a, 2015b), which requires an observer to attend  
356 to a particular feature or stimulus attribute (e.g. orientation) that is present in both the  
357 centre (target) and surround pattern. If attention is directed to a stimulus feature that  
358 is the same for the centre and surround, perceptual surround suppression is enhanced  
359 relative to when the stimulus feature does not match. Our visual stimuli had fixed  
360 spatial frequency, contrast, size, and phase, with the only difference between centre  
361 and surround being the orientation (in order to test the orientation-specificity of the  
362 effect of caffeine). To comment on whether caffeine may have influenced attention,  
363 and specifically ‘feature-based’ visual spatial attention, would require a different  
364 experimental design where more than one stimulus feature is altered. Moreover,  
365 although attention was not explicitly controlled in the present study, spatial attention  
366 was evenly distributed across our visual stimuli – on any given trial, the odd quadrant  
367 was randomly chosen, and so observers did not benefit from focusing their attention  
368 to only one part of their field of view.

369

370 We also considered whether our results might be dependent on habitual caffeine  
371 consumption. On the one hand, tolerance to the effects of caffeine (e.g. on mood,

372 sleep disruption, cardiovascular effects) develops quickly in a matter of days with  
373 frequent caffeine consumption (Fredholm et al., 1999). On the other hand, while some  
374 studies find that high caffeine consumers are more likely than low-moderate  
375 consumers to experience positive effects of caffeine on certain cognitive tasks that  
376 measure speed of processing and reaction time (Attwood et al., 2007; Smit and Rogers,  
377 2000), there are also reports showing improved cognitive performance on attention  
378 and working memory tasks and self-rated alertness following caffeine consumption,  
379 irrespective of caffeine habit (Haskell et al., 2005, Rogers et al., 2003).. We found no  
380 correlation between daily caffeine intake levels and the effect of caffeine on visual  
381 perceptual surround suppression, implying that acute caffeine consumption similarly  
382 influences visual performance on this specific task in habitual and infrequent caffeine  
383 consumers.

384

385 The estimates of daily caffeine intake reported in this study varied from 0.15 to 6.26  
386 mg/kg/day, or 10 to 356 mg/day. This range reflects the full spectrum of typical dietary  
387 caffeine consumption in healthy adults aged 19-30 years (10-90<sup>th</sup> percentile = 24-330  
388 mg/day, data from the United States National Health and Nutrition Examination Survey  
389 2001-2010, see (Fulgoni et al., 2015). The inclusion of participants with very low  
390 caffeine consumption (0-50 mg/day, 24% of participants) is also a strength of this

391 study, as non-consumers of caffeine are notably rare (Haskell et al., 2005).  
392 Furthermore, we considered caffeine intake from multiple sources, which better  
393 reflects normal human consumption, as opposed to studies that have only considered  
394 caffeine content in beverages (e.g. see Mitchell et al 2014). A possible limitation of our  
395 experiments is that we did not tightly control for the time of day of the experiments.  
396 Previous research has shown that the effect of caffeine on somnolence (sleepiness)  
397 and subjective mood is influenced by an interaction between circadian typology and  
398 time of day (Adan et al., 2008). Alertness and mood are not known contributing factors  
399 to our visual perceptual measures. All of our participants were tested between 11am  
400 and 6pm; however, tight control on the visit timing between the first and second  
401 session for a given individual was not enforced. Time of day did not influence the  
402 effect of caffeine on our primary outcome measure (change in suppression index from  
403 baseline to post-caffeine pill, results not shown). Nevertheless, ensuring that the  
404 placebo and caffeine sessions are conducted at the same time of day for each  
405 individual would likely decrease noise in the data, and should be considered for future  
406 studies.

407

408 We observed visual perceptual changes after only a moderate dose of caffeine (200  
409 mg), which was chosen to be comparable to previous work in healthy young adults

410 reporting changes in visual cortical responses with MRI (Laurienti et al., 2002) and  
411 visual perceptual feature binding (Colzato et al., 2005) with caffeine. Other studies  
412 have opted for higher doses (400 mg) of caffeine to produce robust effects (not seen  
413 with 250 mg) in improving mood and cognitive performance (e.g. see Attwood et al  
414 2007). Oral administration of caffeine increases extracellular levels of cortical  
415 acetylcholine in awake rats in a dose-dependent manner (Carter et al., 1995). Whether  
416 the visual perceptual changes observed here with acute caffeine consumption are  
417 similarly dose-dependent is unknown and requires further controlled testing with  
418 caffeine doses that are tailored to a person's weight. Furthermore, given the wide  
419 range of individual factors that may interact with caffeine (e.g. use of alcohol, illicit  
420 drugs, oral contraceptives, anticonvulsant drugs, and smoking), it would be necessary  
421 to measure the pharmacokinetics of caffeine in a given individual over an extended  
422 period of time (e.g. 6 hours).

423

424 In this study, caffeine equally influenced perceptual suppression in the presence of  
425 parallel and orthogonal surround stimuli, unlike donepezil's effect that is specific to  
426 parallel surround stimuli (Kosovicheva et al., 2012). Several distinct neural mechanisms  
427 are considered to contribute to perceptual surround suppression: one that is  
428 orientation specific, and another that is non-orientation specific (Schallmo and Murray,

429 2016). Our findings suggest that caffeine's predominant effect is on the non-  
430 orientation specific aspect of perceptual surround suppression. Our motivation for this  
431 study arose from caffeine's purported effect of increasing cortical acetylcholine. We  
432 chose to focus particularly on the cholinergic system because suppression of perceived  
433 contrast is a spatial contextual phenomenon, and systemic cholinergic enhancement  
434 with donepezil has been shown to influence the spatial spread of human fMRI  
435 responses from early visual areas – particularly V1 (Silver et al., 2008), which is  
436 believed to be the neural locus of perceptual suppression of contrast (Zenger-Landolt  
437 and Heeger, 2003; Haynes et al., 2003; Williams et al., 2003; Pilhaja et al., 2008; Joo et  
438 al., 2012). Further support for primarily considering the cholinergic system comes from  
439 a more recent study by Gratton et al (2017) investigating visual spatial perception in  
440 healthy human observers. In that study, high-contrast flanking distractors were used to  
441 produce a perceptual suppressive effect by reducing an observer's ability to detect a  
442 difference in contrast (in this case, a contrast decrement) of a peripherally placed  
443 target (3° eccentricity). Pharmacological cholinergic enhancement with donepezil  
444 improved detection of the contrast target, but no such effects were seen with  
445 dopaminergic or noradrenergic enhancement (Gratton et al., 2017). We found a similar  
446 facilitatory effect on the spatial suppression of perceived contrast after caffeine  
447 ingestion, which we attribute to a likely enhancement of the cholinergic, rather than

448 noradrenergic or dopaminergic, pathway. However, acetylcholine does not operate in  
449 isolation, but influences other neuromodulator levels. For example, in rodent cortex,  
450 stimulation of muscarinic cholinergic receptors inhibits the release of gamma-  
451 aminobutyric acid (GABA) (Sugita et al., 1991), a key inhibitory neuromodulator  
452 involved in perceptual surround suppression (Yoon et al., 2010). Furthermore,  
453 application of acetylcholine to visual cortical neurones in marmoset monkeys broadens  
454 their orientation tuning – an effect that is attributed to reduced GABA-ergic inhibition  
455 (Zinke et al., 2006). Hence, it is possible that our observed effects result from a  
456 complex cascade of altered neuromodulation, which either only acts on the non-  
457 oriented component of suppression, or alternately reduces the orientation specificity  
458 of the effect. Future work investigating the effect of caffeine on visual perception  
459 could incorporate human neuroimaging methods that enable *in vivo* measurement of  
460 brain metabolites such as GABA (Yoon et al., 2010) to test this idea more directly.

461

## 462 **Conclusions**

463 We show that caffeine affects visual perceptual surround suppression of contrast. The  
464 effect is present 30-60 minutes after ingestion of a commercially available caffeine pill  
465 (i.e. an absolute, moderate 200 mg dose of caffeine), following a period of caffeine  
466 washout (24 hours). Firstly, this finding has practical implications on studies utilising

467 such visual behavioural methods to indirectly investigate centre-surround interactions  
468 in a range of human conditions. Secondly, although the exact biological mechanism of  
469 action of caffeine contributing to the visual perceptual changes observed here is yet  
470 unknown and falls outside the scope of our experimental design, this study provides  
471 evidence from human behavioural work to further understand the mechanisms  
472 underlying perceptual surround suppression. Perceptual surround suppression is  
473 predominantly attributed to the major cortical inhibitory neurotransmitter, GABA. In  
474 this study, we considered the potential for caffeine to exert modulatory effects on  
475 cholinergic pathways, and more recent evidence for visual perceptual facilitatory  
476 effects from cholinergic (and not noradrenergic or dopaminergic) enhancement. Our  
477 results point to the involvement of other neuromodulators, possibly cholinergic, in  
478 perceptual surround suppression. Further work is necessary to elucidate the  
479 mechanism/s of caffeine (e.g. directly via muscarinic cholinergic enhancement or  
480 indirectly via reduction in GABA), that impact on visual perception.

481

482 **6. Acknowledgements:** The authors wish to thank the participants who volunteered  
483 for the study.

484

485 **7. Funding:** This work was supported by an Australian Research Council Discovery  
486 Project Grant (#DP140100157) to author AMM.

487

488 **8. Declaration of conflicting interests:** The authors declare that there is no conflict of  
489 interest.

490

491 **9. References:**

- 492 Adan A, Prat G, Fabbri M, et al. (2008) Early effects of caffeinated and decaffeinated  
493 coffee on subjective state and gender differences. *Prog Neuropsychopharmacol*  
494 *Biol Psych* 32: 1698-1703.
- 495 Adan A and Serra-Grabulosa JM. (2010) Effects of caffeine and glucose, alone and  
496 combined, on cognitive performance. *Hum Psychopharmacol Clin Exp* 25: 310-  
497 317.
- 498 Angelucci A and Bressloff PC. (2006) Contribution of feedforward, lateral and feedback  
499 connections to the classical receptive field center and extra-classical receptive  
500 field surround of primate V1 neurons. *Prog Brain Res* 154: 93-120.
- 501 Attwood AS, Higgs S and Terry P. (2007) Differential responsiveness to caffeine and  
502 perceived effects of caffeine in moderate and high regular caffeine consumers.  
503 *Psychopharmacology (Berl)* 190: 469-477.
- 504 Barch DM, Carter CS, Dakin SC, et al. (2012) The clinical translation of a measure of  
505 gain control: the contrast-contrast effect task. *Schizophr Bull* 38: 135-143.
- 506 Battista J, Badcock DR and McKendrick AM. (2011) Migraine increases centre-surround  
507 suppression for drifting visual stimuli. *PLoS One* 6: e18211.
- 508 Berkowitz BA, Tarver JH and Spector S. (1970) Release of norepinephrine in the central  
509 nervous system by theophylline and caffeine. *Eur J Pharmacol* 10: 64-71.
- 510 Berkowitz BA and Spector S. (1971) The effect of caffeine and theophylline on the  
511 disposition of brain serotonin in the rat. *Eur J Pharmacol* 16: 322-325.
- 512 Blanchard J and Sawers SJ. (1983) The absolute bioavailability of caffeine in man. *Eur J*  
513 *Clin Pharmacol* 24: 93-98.
- 514 Cannon MW and Fullenkamp SC. (1991) Spatial interactions in apparent contrast:  
515 inhibitory effects among grating patterns of different spatial frequencies,  
516 spatial positions and orientations. *Vision Res* 31: 1985-1998.
- 517 Carter AJ, O'Connor WT, Carter MJ, et al. (1995) Caffeine enhances acetylcholine  
518 release in the hippocampus in vivo by a selective interaction with adenosine A1  
519 receptors. *J Pharmacol Exp Ther* 273: 637-642.
- 520 Cavanaugh JR, Bair W and Movshon JA. (2002) Selectivity and spatial distribution of  
521 signals from the receptive field surround in macaque V1 neurons. *J*  
522 *Neurophysiol* 88: 2547-2556.
- 523 Chubb C, Sperling G and Solomon JA. (1989) Texture interactions determine perceived  
524 contrast. *Proc Natl Acad Sci U S A* 86: 9631-9635.
- 525 Cohen J. (2013) The t Test for Means. *Statistical Power Analysis for the Behavioral*  
526 *Sciences*. 2nd ed.: Taylor and Francis, pp 19-74.

- 527 Colzato LS, Fagioli S, Erasmus V, et al. (2005) Caffeine, but not nicotine, enhances visual  
528 feature binding. *Eur J Neurosci* 21: 591-595.
- 529 Cook CE, Tallent CR, Amerson EW, et al. (1976) Caffeine in plasma and saliva by a  
530 radioimmunoassay procedure. *J Pharmacol Exp Ther* 199: 679-686.
- 531 Corradetti R, Pedata F, Pepeu G, et al. (1986) Chronic caffeine treatment reduced  
532 caffeine but not adenosine effects on cortical acetylcholine release. *Br J*  
533 *Pharmac* 88: 671-676.
- 534 Dakin S, Carlin P and Hemsley D. (2005) Weak suppression of visual context in chronic  
535 schizophrenia. *Curr Biol* 15: R822-824.
- 536 Ejima Y and Takahashi S. (1985) Apparent contrast of a sinusoidal grating in the  
537 simultaneous presence of peripheral gratings. *Vision Res* 25: 1223-1232.
- 538 Flevaris AV and Murray SO. (2015a) Feature-based attention modulates surround  
539 suppression. *J Vis* 15: 29, 1-11.
- 540 Flevaris AV and Murray SO. (2015b) Attention determines contextual enhancement  
541 versus suppression in human primary visual cortex. *J Neurosci* 35: 12273-12280.
- 542 Fredholm BB, Battig K, Holmen J, et al. (1999) Actions of caffeine in the brain with  
543 special reference to factors that contribute to its widespread use. *Pharmacol*  
544 *Rev* 51: 83-133.
- 545 Fulgoni VL, 3rd, Keast DR and Lieberman HR. (2015) Trends in intake and sources of  
546 caffeine in the diets of US adults: 2001-2010. *Am J Clin Nutr* 101: 1081-1087.
- 547 Garrett BE and Griffiths RR. (1997) The role of dopamine in the behavioral effects of  
548 caffeine in animals and humans. *Pharmacol Biochem Behav* 57: 533-541.
- 549 Gold JM, Barch DM, Carter CS, et al. (2012) Clinical, functional, and intertask  
550 correlations of measures developed by the Cognitive Neuroscience Test  
551 Reliability and Clinical Applications for Schizophrenia Consortium. *Schizophr*  
552 *Bull* 38: 144-152.
- 553 Golomb JD, McDavitt JR, Ruf BM, et al. (2009) Enhanced visual motion perception in  
554 major depressive disorder. *J Neurosci* 29: 9072-9077.
- 555 Gratton C, Youssef S, Aarts E, et al. (2017) Cholinergic, but not dopaminergic or  
556 noradrenergic, enhancement sharpens visual spatial perception in humans. *J*  
557 *Neurosci* 37: 4405-4415.
- 558 Haskell CF, Kennedy DO, Wesnes KA, et al. (2005) Cognitive and mood improvements  
559 of caffeine in habitual consumers and habitual non-consumers of caffeine.  
560 *Psychopharmacology (Berl)* 179: 813-825.
- 561 Haynes JD, Roth G, Stadler M, et al. (2003) Neuromagnetic correlates of perceived  
562 contrast in primary visual cortex. *J Neurophysiol* 89: 2655-2666.
- 563 Joo SJ, Boynton GM and Murray SO. (2012) Long-range, pattern-dependent contextual  
564 effects in early human visual cortex. *Curr Biol* 22: 781-786.

565 Karas R and McKendrick AM. (2009) Aging alters surround modulation of perceived  
566 contrast. *J Vis* 9: 11: 11-19.

567 Karas R and McKendrick AM. (2012) Age related changes to perceptual surround  
568 suppression of moving stimuli. *Seeing Perceiving* 25: 409-424.

569 Kosasa T, Kuriya Y, Matsui K, et al. (1999) Inhibitory effects of donepezil hydrochloride  
570 (E2020) on cholinesterase activity in brain and peripheral tissues of young and  
571 aged rats. *Eur J Pharmacol* 386: 7-13.

572 Kosovicheva AA, Sheremata SL, Rokem A, et al. (2012) Cholinergic enhancement  
573 reduces orientation-specific surround suppression but not visual crowding.  
574 *Front Behav Neurosci* 6: 61.

575 Laurienti PJ, Field AS, Burdette JH, et al. (2002) Dietary caffeine consumption  
576 modulates fMRI measures. *Neuroimage* 17: 751-757.

577 Levitt JB and Lund JS. (1997) Contrast dependence of contextual effects in primate  
578 visual cortex. *Nature* 387: 73-76.

579 Mitchell DC, Knight CA, Hockenberry J, et al. (2014) Beverage caffeine intakes in the  
580 U.S. *Food Chem Toxicol* 63: 136-142.

581 Modi AA, Feld JJ, Park Y, et al. (2010) Increased caffeine consumption is associated  
582 with reduced hepatic fibrosis. *Hepatology* 51: 201-209.

583 Nehlig A, Daval JL and Debry G. (1992) Caffeine and the central nervous system:  
584 mechanisms of action, biochemical, metabolic and psychostimulant effects.  
585 *Brain Res Rev* 17: 139-170.

586 Pihlaja M, Henriksson L, James AC, et al. (2008) Quantitative multifocal fMRI shows  
587 active suppression in human V1. *Hum Brain Mapp* 29: 1001-1014.

588 Pohanka M. (2014) The effects of caffeine on the cholinergic system. *Mini Rev Med*  
589 *Chem* 14: 543-549.

590 Pohanka M and Dobes P. (2013) Caffeine inhibits acetylcholinesterase, but not  
591 butyrylcholinesterase. *Int J Mol Sci* 14: 9873-9882.

592 Ribeiro JA and Sebastiao AM. (2010) Caffeine and adenosine. *J Alzheimers Dis* 20 Suppl  
593 1: S3-15.

594 Riedel W, Hogervorst E, Lebourg R, et al. (1995) Caffeine attenuates scopolamine-  
595 induced memory impairment in humans. *Psychopharmacol* 122: 158-168.

596 Robertson D, Frolich JC, Carr RK, et al. (1978) Effects of caffeine on plasma renin  
597 activity, catecholamines and blood pressure. *N Engl J Med* 298: 181-186.

598 Rogers SL, Yaminishi Y and Yamatsu K. (1991) E2020 - The pharmacology of a  
599 piperidine cholinesterase inhibitor. In: Becker R and Giacobini E (eds)  
600 *Cholinergic basis for Alzheimer therapy*. Boston: Birkhauser, pp 314-320.

601 Schallmo MP and Murray SO. (2016) Identifying separate components of surround  
602 suppression. *J Vis* 16: 2: 1-12.

603 Schallmo MP, Sponheim SR and Olman CA. (2015) Reduced contextual effects on visual  
604 contrast perception in schizophrenia and bipolar affective disorder. *Psychol*  
605 *Med* 45: 3527-3537.

606 Serra-Grabulosa JM, Adan A, Falcon C, et al. (2010) Glucose and caffeine effects on  
607 sustained attention: an exploratory fMRI study. *Hum Psychopharmacol Clin Exp*  
608 25: 543-552.

609 Shushruth S, Nurminen L, Bijanzadeh M, et al. (2013) Different orientation tuning of  
610 near- and far-surround suppression in macaque primary visual cortex mirrors  
611 their tuning in human perception. *J Neurosci* 33: 106-119.

612 Silver MA, Shenhav A and D'Esposito M. (2008) Cholinergic enhancement reduces  
613 spatial spread of visual responses in human early visual cortex. *Neuron* 60: 904-  
614 914.

615 Smit HJ and Rogers PJ. (2000) Effects of low doses of caffeine on cognitive  
616 performance, mood and thirst in low and higher caffeine consumers.  
617 *Psychopharmacology (Berl)* 152: 167-173.

618 Sugita S, Uchimura N, Jiang ZG, et al. (1991) Distinct muscarinic receptors inhibit  
619 release of gamma-aminobutyric acid and excitatory amino acids in mammalian  
620 brain. *Proc Natl Acad Sci U S A* 88: 2608-2611.

621 Turpin A, Lawson DJ and McKendrick AM. (2014) PsyPad: a platform for visual  
622 psychophysics on the iPad. *J Vis* 14: 16: 1-7.

623 Wetherill GB and Levitt H. (1965) Sequential estimation of points on a psychometric  
624 function. *Br J Math Stat Psychol* 18: 1-10.

625 Williams AL, Singh KD and Smith AT. (2003) Surround modulation measured with  
626 functional MRI in the human visual cortex. *J Neurophysiol* 89: 525-533.

627 Xing J and Heeger DJ. (2000) Center-surround interactions in foveal and peripheral  
628 vision. *Vision Res* 40: 3065-3072.

629 Xing J and Heeger DJ. (2001) Measurement and modeling of center-surround  
630 suppression and enhancement. *Vision Res* 41: 571-583.

631 Yoon JH, Maddock RJ, Rokem A, et al. (2010) GABA concentration is reduced in visual  
632 cortex in schizophrenia and correlates with orientation-specific surround  
633 suppression. *J Neurosci* 30: 3777-3781.

634 Yoon JH, Rokem AS, Silver MA, et al. (2009) Diminished orientation-specific surround  
635 suppression of visual processing in schizophrenia. *Schizophr Bull* 35: 1078-1084.

636 Yu C, Klein SA and Levi DM. (2001) Surround modulation of perceived contrast and the  
637 role of brightness induction. *J Vis* 1: 18-31.

638 Yu C and Levi DM. (2000) Surround modulation in human vision unmasked by masking  
639 experiments. *Nat Neurosci* 3: 724-728.

640 Zenger-Landolt B and Heeger DJ. (2003) Response suppression in v1 agrees with  
641 psychophysics of surround masking. *J Neurosci* 23: 6884-6893.  
642 Zhuang X, Chen Y, Zhuang X, et al. (2016) Impaired Center-Surround Suppression in  
643 Patients with Alzheimer's Disease. *J Alzheimers Dis* 5: 1101-1108.  
644 Zinke W, Roberts MJ, Guo K, et al. (2006) Cholinergic modulation of response  
645 properties and orientation tuning of neurons in primary visual cortex of  
646 anaesthetized Marmoset monkeys. *Eur J Neurosci* 24: 314-328.  
647